Menu Search
Equities

KeyMed Biosciences Inc

64Z:DUS

KeyMed Biosciences Inc

Actions
  • Price (EUR)4.56
  • Today's Change-0.14 / -2.98%
  • Shares traded--
  • 1 Year change-23.36%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 18:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.

  • Revenue in HKD (TTM)87.71m
  • Net income in HKD-798.20m
  • Incorporated2018
  • Employees1.12k
  • Location
    KeyMed Biosciences Inc18 Biotown Middle Road Building D2Chengdu Tianfu International BiotownCHENGDU 610219ChinaCHN
  • Websitehttps://www.keymedbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.